Amarin Revenue 2006-2021 | AMRN

Amarin revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Amarin Annual Revenue
(Millions of US $)
2020 $614
2019 $430
2018 $229
2017 $181
2016 $130
2015 $82
2014 $54
2013 $26
2012 $
2011 $
2010 $
2009 $
2008 $
2007 $
2006 $1
2005 $1
Amarin Quarterly Revenue
(Millions of US $)
2021-06-30 $154
2021-03-31 $142
2020-12-31 $167
2020-09-30 $156
2020-06-30 $135
2020-03-31 $155
2019-12-31 $143
2019-09-30 $112
2019-06-30 $101
2019-03-31 $73
2018-12-31 $77
2018-09-30 $55
2018-06-30 $53
2018-03-31 $44
2017-12-31 $54
2017-09-30 $47
2017-06-30 $45
2017-03-31 $35
2016-12-31 $39
2016-09-30 $33
2016-06-30 $33
2016-03-31 $26
2015-12-31 $27
2015-09-30 $21
2015-06-30 $18
2015-03-31 $16
2014-12-31 $16
2014-09-30 $14
2014-06-30 $13
2014-03-31 $11
2013-12-31 $10
2013-09-30 $8
2013-06-30 $6
2013-03-31 $2
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2008-12-31
2008-06-30
2008-03-31
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-12-31 $0
2006-09-30 $0
2006-06-30
2006-03-31
2005-12-31 $1
2005-09-30
2005-06-30
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.135B $0.614B
Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29